Thomas K.  Equels net worth and biography

Thomas Equels Biography and Net Worth

THOMAS K. EQUELS, Esq., has been a Director and serves as our Executive Vice Chairman (since 2008), Chief Executive Officer (since 2016) and President (since 2015). Mr. Equels is the owner of and former President and Managing Director of the Equels Law Firm headquartered in Miami, Florida that focuses on litigation. For over a quarter century, Mr. Equels has represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters’ Degree from Troy. He is a member of the Florida Bar Association and the American Bar Association.

What is Thomas K. Equels' net worth?

The estimated net worth of Thomas K. Equels is at least $317,389.57 as of March 15th, 2024. Mr. Equels owns 716,455 shares of AIM ImmunoTech stock worth more than $317,390 as of March 28th. This net worth estimate does not reflect any other investments that Mr. Equels may own. Additionally, Mr. Equels receives a salary of $1,240,000.00 as CEO at AIM ImmunoTech. Learn More about Thomas K. Equels' net worth.

How old is Thomas K. Equels?

Mr. Equels is currently 71 years old. There are 4 older executives and no younger executives at AIM ImmunoTech. Learn More on Thomas K. Equels' age.

What is Thomas K. Equels' salary?

As the CEO of AIM ImmunoTech Inc., Mr. Equels earns $1,240,000.00 per year. Learn More on Thomas K. Equels' salary.

How do I contact Thomas K. Equels?

The corporate mailing address for Mr. Equels and other AIM ImmunoTech executives is 2117 SW HIGHWAY 484, OCALA FL, 34473. AIM ImmunoTech can also be reached via phone at (352) 448-7797 and via email at [email protected]. Learn More on Thomas K. Equels' contact information.

Has Thomas K. Equels been buying or selling shares of AIM ImmunoTech?

Thomas K. Equels has not been actively trading shares of AIM ImmunoTech during the last quarter. Learn More on Thomas K. Equels' trading history.

Are insiders buying or selling shares of AIM ImmunoTech?

In the last twelve months, AIM ImmunoTech insiders bought shares 8 times. They purchased a total of 331,489 shares worth more than $127,422.78. The most recent insider tranaction occured on March, 21st when Director Nancy Bryan bought 38,462 shares worth more than $15,000.18. Insiders at AIM ImmunoTech own 0.0% of the company. Learn More about insider trades at AIM ImmunoTech.

Information on this page was last updated on 3/21/2024.

Thomas K. Equels Insider Trading History at AIM ImmunoTech

See Full Table

Thomas K. Equels Buying and Selling Activity at AIM ImmunoTech

This chart shows Thomas K. Equels's buying and selling at AIM ImmunoTech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AIM ImmunoTech Company Overview

AIM ImmunoTech logo
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Read More

Today's Range

Now: $0.44
Low: $0.43
High: $0.46

50 Day Range

MA: $0.41
Low: $0.33
High: $0.45

2 Week Range

Now: $0.44
Low: $0.32
High: $0.75

Volume

152,625 shs

Average Volume

219,193 shs

Market Capitalization

$21.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A